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Abstract
Background: There are unpredictable inter-individual differences in sensitivity to psoralen-UVA (PUVA) photochemother-
apy, used to treat skin diseases including psoriasis. Psoralens are metabolised by cytochrome P450 enzymes (P450), and we
hypothesised that variability in cutaneous P450 expression may influence PUVA sensitivity. We previously showed that P450
CYP1B1 was abundantly expressed in human skin and regulated by PUVA, and described marked inter-individual differences
in cutaneous CYP1B1 expression.
Objectives: We investigated whether CYP1B1 made a significant contribution to 8-methoxypsoralen (8-MOP) metabolism,
and whether individuality in CYP1B1 activity influenced PUVA sensitivity.
Methods: We used E. coli membranes co-expressing various P450s and cytochrome P450 reductase (CPR) to study 8-MOP
metabolism and cytotoxicity assays in CYP1B1-expressing mammalian cells to assess PUVA sensitivity.
Results:We showed that P450s CYP1A1, CYP1A2, CYP1B1, CYP2A6 and CYP2E1 influence 8-MOP metabolism. As CYP1B1 is the
most abundant P450 in human skin, we further demonstrated that: (i) CYP1B1 interacts with 8-MOP (ii) metabolism of the
CYP1B1 substrates 7-ethoxyresorufin and 17-b-estradiol showed concentration-dependent inhibition by 8-MOP and (iii)
inhibition of 7-ethoxyresorufin metabolism by 8-MOP was influenced by CYP1B1 genotype. The influence of CYP1B1 on
PUVA cytotoxicity was further investigated in a Chinese hamster ovary cell line, stably expressing CYP1B1 and CPR, which
was more sensitive to PUVA than control cells, suggesting that CYP1B1 metabolises 8-MOP to a more phototoxic
metabolite(s).
Conclusion: Our data therefore suggest that CYP1B1 significantly contributes to cutaneous 8-MOP metabolism, and that
individuality in CYP1B1 expression may influence PUVA sensitivity.
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Introduction
Psoralen-UVA (PUVA) photochemotherapy is widely used to
treat psoriasis and other common skin diseases [1,2]. Importantly,
PUVA is of superior efficacy to some of the highly costly biologic
drugs, with unknown long-term safety, that are increasingly being
used to treat psoriasis [3]. There is considerable individuality in
PUVA sensitivity, and high cumulative PUVA exposure signifi-
cantly increases risk of skin cancer [4]. To date, no reliable
predictors of PUVA sensitivity have been identified, although
there is increasing interest in genetic response predictors [5].
Knowledge of genetic or phenotypic determinants of PUVA
sensitivity would facilitate the identification of individuals at
increased risk of acute or chronic adverse effects of PUVA
treatment.
The most commonly clinically used psoralen is the furanocou-
marin, 8-methoxypsoralen (8-MOP), used in systemic and topical
PUVA therapy. Previous studies have shown correlations between
serum 8-MOP concentrations and PUVA sensitivity, assessed by
minimal phototoxic dose (MPD), although there is considerable
inter-individual variability in 8-MOP serum levels following oral
administration [6–9]. This individuality may reflect inter-individ-
ual differences in 8-MOP metabolism, but this also suggests that
variation in hepatic P450 gene expression may not be the only
contributor and that cutaneous drug metabolising enzymes (DME)
may influence PUVA sensitivity. There is considerable evidence
that variation in DME, in particular cytochrome P450, activity
can be a major determinant of individuality in drug sensitivity
[10,11]. In support of this hypothesis, we have shown that PUVA
induces the cutaneous expression of several P450s, and reported
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marked inter-individual variability in constitutive and inducible
P450 expression [12,13].
P450s are a multigene family of inducible Phase I DMEs which,
together with their redox partner NADPH cytochrome P450
reductase (CPR), catalyse the oxidative metabolism of many
endogenous compounds, drugs and xenobiotics [14–16]. In
general, compounds which are P450 inducers are also P450
substrates or inhibitors [17]. P450s have been implicated in
psoralen metabolism in insects [18,19] and vertebrates [20], where
different furanocoumarin derivatives induce or inhibit multiple
P450s. In contrast, human P450s involved in 8-MOP metabolism
have not been fully characterised, although furanocoumarins have
been shown to inhibit human CYP1A2 [21] and CYP1B1 [22],
polymorphisms in CYP2A13 shown to influence the metabolism of
5-methoxypsoralen [23] and the furanocoumarin chalepsin
identified as both a substrate and inhibitor of coumarin
hydroxylase (CYP2A6) [24].
We previously showed that the predominantly extra-hepatic
CYP1B1 was the most abundantly expressed P450 in human
skin, with marked inter-individual variability in both constitu-
tive expression and in regulation by UVR and PUVA [12].
Pharmacogenetic polymorphisms result in a population distri-
bution of alleles of many P450 including CYP1B1 (CYP1B1*1
to CYP1B1*26, http://www.cypalleles.ki.se/cyp1b1.htm) result-
ing in altered gene expression and catalytic activity. We
therefore investigated whether CYP1B1 metabolises 8-MOP,
and whether individuality in CYP1B1 expression influences
PUVA sensitivity. Our data suggest that CYP1B1 significantly
contributes to cutaneous 8-MOP metabolism, and that
individuality in CYP1B1 expression may influence PUVA
sensitivity.
Materials and Methods
Ethical Approval
The use of human skin samples was approved by the Tayside
Committee on Medical Research Ethics (091/99). All patients
were given a patient information sheet detailing the study and
given at least 24 h to digest this before providing written informed
consent on a standard consent form approved by the Tayside
Committee on Medical Research Ethics.
Co-expression of Human CYP1B1 and CPR in E. coli
Construction of CYP1B1 and CPR expression plasmids has been
described previously [25]. The CYP1B1 alleles CYP1B1*1,
CYP1B1*3 and CYP1B1*4 were co-expressed with CPR in E. coli
JM109 cells and membranes prepared as described previously
[26]. P450 content was determined spectrophotometrically [27],
and CPR activity estimated by cytochrome c reduction [26]. 8-
MOP metabolism was assessed by HPLC analysis, as previously
described [28]. Western blot analysis was performed after cells
were pre-incubated with 0.05% PBS–EDTA, harvested by
trypsinisation (0.25% trypsin-EDTA) and protein content assessed
by Bradford assay [29]. Solubilised protein lysates or human liver
microsomes were separated by SDS-PAGE, transferred onto
Hybond-ECL nitrocellulose membranes (Amersham, UK) and
probed with CYP1B1 (BD Gentest, Woburn, MA) and CPR
antibodies [30], as previously described [25].
Interaction of 8-MOP with Recombinant P450s
Furanocoumarin metabolism was assessed using a substrate
depletion assay, as previously described [31,32]. Assays were
performed with 5 mM 8-MOP in 160 ml reaction mixtures
containing 50 pmol recombinant P450 membranes or 250 mg
human liver microsomes (Tayside Tissue Bank, positive controls)
in 50 mM phosphate buffer (PB) pH 7.4. After 3 min 37uC pre-
incubation, reactions were initiated by 40 ml 5 mM NADPH
containing 30 mM glutathione (GSH) in 50 mM PB (pH 7.4).
Reactions were incubated for 10 min in a shaking water bath at
37uC, terminated by the addition of 100 ml ice-cold methanol
containing 3% perchloric acid, and placed on ice for 10 min.
Zero-time controls were terminated before the addition of P450
membranes; no-NADPH control reactions were initiated with
20 ml 50 mM PB (pH 7.4) containing 30 mM GSH. Samples were
vortexed for 1 min, centrifuged at 12 000 rpm for 5 min,
supernatants collected and analysed by HPLC analysis [28].
The Influence of 8-MOP on Recombinant Human CYP1B1
Activity
The role of CYP1B1 in 8-MOP metabolism was confirmed using
17-b-estradiol 2-hyroxylase, 4-hydroxylase and 7-ethoxyresorufin
O-deethylase (EROD) assays. Estradiol hydroxylase assays were
performed as previously described [25] using 20 mM 17-b-
estradiol in the absence (methanol solvent control) or the presence
of 8-MOP (1, 10, or 100 mM). EROD activity was determined as
previously described [33], but modified in 96-well plate format
with quadruplicate replicates, using a Fluoroskan fluorescence
reader (Labsystems, Cambridge, UK). Each 200 ml incubation
mixture contained PBS, 4 mM 7-ethoxyresorufin, 250 mM
NADPH, 5 pmol recombinant CYP1B1, and 8-MOP (0–
180 mM, serially diluted). Assays were performed at 37uC,
fluorescence readings recorded every 20 s for 3 min at
lex = 530 nm, lem = 584 nm and fluorescence production (arbi-
trary fluorescence units) against time relative to control incuba-
tions used to assess 8-MOP inhibition. Calibration curves were
constructed with authentic resorufin standards and linear regres-
sion analysis used to calculate the amount of resorufin formed in
each test sample. Enzyme kinetics for CYP1B1-catalysed EROD
activity were determined at substrate concentrations from 0.002 to
2 mM. Apparent Km and Vmax values were estimated by non-
linear regression analysis (GraFit software program, UK) of the
substrate concentration [S]-enzyme activity [V], fitting data to a
Michaelis-Menten model. Similarly, the concentration of 8-MOP
required to inhibit 50% (IC50) of CYP1B1-catalysed EROD at Km
concentration was calculated. Experiments were performed using
Table 1. Metabolism of 8-MOP by human recombinant P450s
and human liver microsomesa.
P450 Turnover (min21)
CYP1A1 0.2960.07
CYP1A2 0.6360.08
CYP1B1 0.2460.05
CYP2A6 0.4860.04
CYP2E1 0.0860.03
CPR NDc
Microsomesb 4.7364.15
aAssays were performed with 5 mM 8-MOP as described in Materials and
Methods. Each value represents mean 6 SD of three determinations.
bMean 6 SD of specific activity (n = 3) of microsomes from 3 human livers as
pmol/min/mg protein.
cND; Not detected.
doi:10.1371/journal.pone.0075494.t001
CYP1B1 Expression Influences PUVA Sensitivity
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e75494
six 8-MOP concentrations 8-MOP (0, 1.17, 2.34, 4.69, 9.38 and
37.50 mM) and four 7-ethoxyresorufin concentrations equivalent
to 1/2 Km, Km, 2 Km and 5 Km - mode of inhibition was
determined by Lineweaver-Burk plots.
Stable Expression of Human CYP1B1 and CPR in CHO
Cells
CHO cell lines stably over-expressing CYP1B1 and CPR were
generated as previously described [34]. CHO cells were
maintained at 37uC/5% CO2 in Dulbecco’s Modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 1 U/ml
each of hypoxanthine and thymine (Invitrogen, Paisley-UK).
Similar culture conditions, with the addition of G-418 (400 mg/
ml), were used for CHO cells stably expressing CPR (CHO-CPR).
CHO cells stably co-expressing CYP1B1 and CPR (CHO-1B1/
CPR) were maintained at 37uC/5% CO2, but in hypoxanthine
and thymine-free DMEM supplemented with 10% dialysed FBS
and the appropriate selection (0.3 mM MTX and 400 mg/ml G-
418). HaCaT keratinocytes were grown to 80% confluence in
DMEM supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM gluta-
mine. Cells were harvested and microsomes prepared as described
previously [26]. HaCaT cell microsomes and microsomes from
human skin biopsies obtained from peri-lesional skin from psoriasis
patients [12,13] were used to investigate functional CYP1B1
expression using EROD assays.
UVA and PUVA Treatment
To investigate CHO cell sensitivity to UVA and PUVA, actively
dividing cells (10000 cells/well) were seeded in 96-well plates
(Iwaki, Japan) in quadruplicates in 200 ml culture medium and
allowed to grow for 18–20 h. Cells were irradiated at room
temperature with a UVA source (266 ft Cosmolux 15500/100 W,
1.7 mW/cm2 (320–400 nm; lmax= 365 nm), Germany) through
a 4 mm thick window glass filter at multiple UVA doses (0, 1.5, 4.0
and 7.5 J/cm2), monitoring irradiance with a Waldmann UV
meter equipped with UVA detector. Control samples were kept in
the dark under the same conditions. To model PUVA treatment,
cells were pre-incubated with varying concentrations of 8-MOP
(0–5 mM) in PBS at 37uC for 40 min and cells irradiated as
described above. Control samples were pre-incubated with solvent
and kept in the dark under the same conditions. After each
treatment, fresh culture medium was added and cells returned to an
Figure 1. 8-MOP influences CYP1B1 catalytic activity. The influence of 8-MOP on: (A) EROD activity and (B) 17-b-estradiol hydroxylase activity
in E. coli membranes co-expressing CYP1B1 and CPR. 17-b-estradiol 4-hydroxylase and 17-b-estradiol 2-hydroxylase activities were determined as
described in Materials and Methods and are presented as mean6 SD of % control 17-b-estradiol 4-hydroxylation. (C) Dose-response curve for 8-MOP
dependent CYP1B1 inhibition. EROD activity was assessed as described in Materials and Methods and data presented as mean 6 SD percentage of
control activity of three independent determinations. (D) Lineweaver-Burk plots for inhibition of CYP1B1 activity by 8-MOP. CYP1B1 catalysed EROD
activity was determined at varying concentrations of 8-MOP and 7-ethoxyresorufin, as described in Materials and Methods. Data represent linear
regression analysis of the mean of transformed data for three independent determinations.
doi:10.1371/journal.pone.0075494.g001
Table 2. CYP1B1*4 influences 8-MOP metabolism.
CYP1B1 allelic
variant 8-MOP Turnover IC50
a
(min21) (ng/ml) ( mM)
CYP1B1*1 0.2760.05 369643 1.760.20
CYP1B1*3 0.2560.03 326615 1.560.07
CYP1B1*4 0.1260.02 130622 0.660.10
aIC50 for 8-MOP against CYP1B1-dependent EROD activity determined using E.
coli membranes co-expressing human individual CYP1B1 alleles and CPR as
described in Materials and Methods. Data represents the mean 6 SD of
triplicate determinations.
doi:10.1371/journal.pone.0075494.t002
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incubator at 37uC/5%CO2 for 24 h. Cell viability was assessed
using neutral red uptake assays [35]; quadruplicate replicates of
each treatment were performed, and each experiment repeated
twice. PUVA cytotoxicity data was assessed by non-linear regression
analysis for dose-response curves (IC50) fitting (GraFit software
program, UK) and unpaired Student’s t-test (Statview 4.1 software).
Tissue Immunohistochemistry
To confirm CYP1B1 and CPR protein expression in human skin,
frozen non-lesional skin biopsies from patients with psoriasis, and
from whom informed consent was obtained and approved by
Tayside Committee on Medical Research Ethics, were analysed by
immunohistochemistry using polyclonal antibodies against human
CYP1B1 (BD Gentest, Woburn, MA) and human CPR [25,30].
4 mm frozen sections were cut from 4 mm full-thickness punch
biopsies and processed in a standard immunohistochemical
procedure with microwave antigen retrieval and horseradish-
peroxidase-labelled streptavidin detection system and counter-
stained with haematoxylin-eosin.
Results
8-MOP Metabolism by Recombinant P450s
Human liver microsomes from three different individuals
expressing multiple human P450s (positive controls) and E. coli
membranes co-expressing individual P450s present in human skin
(CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2E1) and CPR were
used to identify P450s involved in 8-MOP metabolism. 8-MOP
was metabolized by each of three human liver microsomes, with
specific activities of 1.31, 3.53 and 9.35 pmol/min/mg protein,
respectively (mean 6 SD; 4.7364.15, Table 1). Each recombinant
P450 metabolised 8-MOP in the presence of CPR (Table 1), but
not in reactions containing CPR alone or in control experiments
omitting CPR or the essential cofactor NADPH (data not shown).
8-MOP metabolism in human liver microsomes and by recom-
binant CYP1A1, CYP1A2 and CYP1B1 was decreased in the
presence of the potent, selective CYP1 P450 family inhibitor a-
naphthoflavone (5 mM), where microsomal, CYP1A1-, CYP1A2-
and CYP1B1-dependent 8-MOP metabolism was reduced to 59,
53, 34 and 62% of control levels, respectively. Of the catalytically
active P450s tested, CYP1B1 is most abundantly expressed in
human skin [12], and was therefore selected as the focus of
additional studies.
8-MOP Inhibits CYP1B1 Activity
Using E. coli membranes co-expressing recombinant CYP1B1
and CPR, we showed that 8-MOP inhibited CYP1B1-dependent
EROD and 17-b-estradiol hydroxylase activities in a concentra-
tion dependent manner (Figures 1A & 1B). The apparent Km for
CYP1B1-dependent EROD activity was 0.3360.03 mM (n= 3),
consistent with previous literature [25]. The addition of 8-MOP
decreased CYP1B1-dependent EROD activity in a concentration-
dependent manner with an estimated IC50 of 2.060.1 mM
(Figure 1C) and Ki of 3.5861.00 mM (n= 3). Further, the IC50
for 8-MOP metabolism by the low activity CYP1B1*4 allele was
significantly reduced relative to the ‘‘wild-type’’ CYP1B1*1, and
CYP1B1*3 alleles (Table 2).
To determine the potency and mode of 8-MOP inhibition of
CYP1B1, further experiments were performed using six 8-MOP
concentrations and four 7-ethoxyresorufin concentrations as
described in Materials and Methods. Analysis of enzyme kinetic
data by Lineweaver-Burk plots suggested that 8-MOP inhibited
CYP1B1 by mixed inhibition (Figure 1D).
Evidence for the Presence of Catalytically Active CYP1B1
in Human Skin
EROD activity was determined in microsomes isolated from
human skin and HaCaT keratinocytes, with turnover rates of
0.1060.05 and 0.3060.03 pmol/min/mg protein, respectively.
EROD metabolism was significantly reduced in the presence of
5 mM 8-MOP (90% inhibition), and following pre-incubation of
HaCaT microsomes with a CYP1B1-specific antibody (60%
inhibition) (Figure 2A). In contrast, incubation of microsomes
with control CYP3A4 antibodies had no effect on EROD activity.
Consistent with our previous data, cutaneous CYP1B1 and CPR
expression was confirmed by immunohistochemistry (Figure 2B).
Nuclear CPR localization in human skin was unexpected and may
reflect a tissue fixation or processing artefact.
CYP1B1 and CPR Over-expression Influences PUVA
Sensitivity in CHO Cells
We have previously reported that CHO cells have no
constitutive P450 and limited CPR expression, but have been
engineered to stably over-express CYP1B1 and CPR, individually
and in combination [34] (Figure 3A). As described in Materials
and Methods, the presence of catalytically active CYP1B1 was
confirmed using EROD assays in total protein cell lysates from
each cell line. While there was no EROD activity in control CHO
Figure 2. The presence of catalytically active CYP1B1 in human
skin. (A) Inhibition of EROD activity by 8-MOP and CYP1B1 polyclonal
antibodies in HaCaT keratinocyte microsomes. EROD activity was
determined as described in Materials and Methods. Pre-incubation
was performed with 8-MOP (5 mM), and anti-CYP1B1 and anti-CYP3A4
polyclonal antibodies as described in Materials and Methods. (B)
Cytochrome P450 CYP1B1 and CPR expression in non-lesional skin of
patients with psoriasis was assessed as described in Materials and
Methods. (i) Negative (no antibody) control (ii) Hematoxylin-Eosin stain
(iii) CYP1B1 antibody (1:1000) stain and (iv) CPR antibody (1:2000) stain.
doi:10.1371/journal.pone.0075494.g002
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or CHO-CPR expressing cells, CHO-1B1/CPR expressing cells
metabolised ethoxy resorufin (EROD activity 1.8560.87 pmol/
min/mg protein; n= 5).
UVA alone at doses up to 7.5 J/cm2 and 8-MOP (0–5 mM)
alone showed no significant cytotoxicity to CHO cells (Figure 3B
& 3C). However, significant cytotoxicity was seen when CHO cells
were exposed to 8-MOP and then irradiated with UVA, with
dose-dependent effects of both 8-MOP concentration and UVA
dose (Figure 3C). Optimal dose-dependency cytotoxicity was seen
at a combined UVA dose of 4 J/cm2 and an 8-MOP concentra-
tion range of 0–5 mM (Figure 3C).
8-MOP alone was not cytotoxic and appeared to promote cell
proliferation in each cell line tested, although this was most evident
for the catalytically-active CHO-1B1/CPR cell line (Figure 3D). In
contrast, PUVA was cytotoxic to all the cell lines tested (Figure 3D).
While the cytotoxic effect of PUVA on the CHO and the CHO-
CPR cell lines were similar (p = 0.268, Table 3), the CHO-1B1/
CPR cell line was significantly more sensitive to PUVA cytotoxicity
than the parental CHO cell line (p = 0.002) or the CHO-1B1/CPR
cell line (p,0.001). The addition of catalytically active CYP1B1 to
CHO cells resulted in an approximately 2.6-fold increase in
PUVA phototoxicity.
Discussion
Psoralens, particularly systemic and topical 8-MOP, are widely
used in dermatology in PUVA photochemotherapy. However, the
enzymes involved in 8-MOP metabolism have not been fully
characterised, and it is not known whether individuality in 8-MOP
metabolism may influence PUVA sensitivity. Previous studies have
described O-demethylation, hydroxylation and epoxidation as
important mechanisms of 8-MOP metabolism [6,36]. This,
together with the observation that phenobarbital and a-naphtho-
flavone induce 8-MOP metabolism in vivo and in vitro [36], suggest
a role for P450s in 8-MOP metabolism, and an inhibitory effect of
furanocoumarins on human CYP1A2 has recently been confirmed
[21]. However, with the exception of the predominantly hepatic
CYP2A6 [37,38] and respiratory tract-specific CYP2A13 [23,39],
cutaneous P450s active in 8-MOP metabolism have not been
characterised.
We have previously shown that the cutaneous expression of
several P450s, including CYP1B1, CYP2S1 and CYP2E1, is
regulated by PUVA in vivo, and have shown marked individuality
in gene expression [12]. CYP1B1 is the most abundantly expressed
P450 in human skin, and furanocoumarins have been shown to
inhibit CYP1B1 activity [22]. 8-MOP is highly structurally similar
to the CYP2A6 substrate coumarin, another competitive CYP1B1
inhibitor [40], suggesting that cutaneous CYP1B1 expression may
Figure 3. CYP1B1 expression in CHO cells influences psoralen-UVA sensitivity. (A) Western blot analysis of CYP1B1 and CPR expression in
modified CHO cell lines was performed as described in Materials and Methods (lane 1, CHO-1B1/CPR cells; lane 2, CHO-CPR cells; lane 3, CHO cells;
lane 4, control E. coli membranes). The influence of (B) UVA and (C) PUVA treatment on CHO cell viability and (D) PUVA treatment on CHO-1B1/CPR
and CHO-CPR cells was assessed by NRUA [35]. Data are presented from representative experiments and expressed as mean 6 SD of duplicate
determinations compared to dark control (for the majority of cell lines, experimental errors were very small and SD values are therefore too small to
be visible).
doi:10.1371/journal.pone.0075494.g003
Table 3. Modulation of PUVA cytotoxicity in CHO cells by
CYP1B1 expression.
Cell line IC50
a
(ng/ml) ( mM) p-Value
CHO 461647 2.1360.22
CHO-CPR 540648 2.5060.22 0.268b
CHO-1B1/CPR 241623 1.1160.11 0.002b
,0.001c
aIC50 for 8-MOP in the presence of UVA (4 J/cm
2) determined as described in
Materials and Methods. Data represents the mean 6 SE of 5 experiments.
bp-value as compared with control CHO cell line.
cp-value as compared with CHO-CPR cell line.
doi:10.1371/journal.pone.0075494.t003
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influence PUVA sensitivity. We found that 8-MOP inhibits
CYP1B1-dependent EROD and 17-b-estradiol hydroxylase activ-
ities in a concentration-dependent manner, with estimated IC50
values for EROD similar to those reported for another
furanocoumarin, bergamottin [41]. Moreover, the inhibition of
CYP1B1-dependent EROD metabolism by 8-MOP was demon-
strated in both human skin microsomes and in a human
keratinocyte cell line. These data suggest that 8-MOP may be a
CYP1B1 substrate and demonstrate that 8-MOP and/or its
metabolite(s) are potent CYP1B1 inhibitors.
The inhibition of CYP1B1 by 8-MOP and/or metabolites could
occur by direct selective inhibition and/or mechanism-based
inactivation as reported with other P450s [21]. Previously, 8-MOP
and other furanocoumarin derivatives have been shown to be
potent mechanism-based P450 inhibitors [38,42], with the
generation of a reactive intermediate by initial oxidation of the
furan ring to form furanoepoxide intermediates that readily react
with target residue(s) in the active site of the P450 [24]. Currently,
it is not known whether 8-MOP inhibits the catalytic activity of
CYP1B1 in vivo, however clinical data suggest that this is likely
[37,43].
We were therefore interested to find that, using a modified
CHO cell line stably over-expressing recombinant human CYP1B1
together with its redox partner CPR, CHO-1B1/CPR cells were
significantly more susceptible to PUVA cytotoxicity than control
cell lines. These data strongly suggest that CYP1B1may metabolise
8-MOP to product(s) which are more phototoxic than the parent
compound. In support of this hypothesis, we have recently shown
that CYP1B1 is induced by UVB, but is not significantly induced
by UVA in HaCaT keratinocytes [29], consistent with increased
PUVA sensitisation arising from altered 8-MOP metabolism.
Evidence from several cell line models additionally suggests that
PUVA is a source of reactive oxygen species leading to oxidative
stress [44], genotoxic effects and the formation of DNA
photoadducts [45]. It is therefore conceivable that the increased
PUVA cytotoxicity in the CHO-1B1/CPR cell line may reflect
increased genotoxicity and DNA photoadduct formation and this
requires further study.
CYP1B1 is polymorphic, with a population distribution of alleles
with altered catalytic activity [46]. In particular, the CYP1B1*3
allele (Val432Leu) allele has been shown to significantly influence
the conversion of estradiol to 4-hydroxyestradiol [25] and the
CYP1B1*4 allele (Asn453Ser) to have reduced protein expression
and catalytic activity, as a consequence of enhanced polyubiquitin-
mediated degradation [47]. Our finding that 8-MOP metabolism
is also impaired in cells expressing the CYP1B1*4 allele is therefore
intriguing, and suggests that both genetically determined and
transcriptionally regulated inter-individual differences in CYP1B1
activity may influence PUVA sensitivity. As PUVA is photo-
carcinogenic, with high cumulative PUVA exposure incurring a
significantly increased risk of skin cancer [4], it will be of particular
interest in future clinical studies to investigate whether CYP1B1
genotype influences PUVA-associated skin cancer risk, and
whether CYP1B1 genotype or phenotype influences PUVA
sensitivity.
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